Within the field of thyroid carcinoma, this is best exemplified by the use of selective inhibitors targeting BRAF V600E mutations in anaplastic and poorly differentiated thyroid cancers, as well as tumor-agnostic approvals, and RET fusions in differentiated thyroid cancer versus RET mutations in medullary thyroid cancer [1,2,3,4]. This evidence concerns the gene BRAF and thyroid gland carcinoma.